搜索
1

1

新闻中心
/
/
The first in China | AIVD launched six diagnostic raw materials for self-developed new thrombosis

The first in China | AIVD launched six diagnostic raw materials for self-developed new thrombosis

  • Time of issue:2022-04-14
  • Views:

(Summary description)The pathological process of thrombotic diseases involves three major systems: vascular endothelium, coagulation and fibrinolysis. It has been confirmed that in the prethrombotic state, the vascular endothelium, coagulation and fibrinolysis systems have been changed. TAT, PIC, TM, t-PAIC, FDP and D-Dimer are effective responses to the early changes of the body's vascular endothelium, coagulation and fibrinolysis systems. effective indicator. It is suitable for early diagnosis and risk assessment of high-risk groups of thrombosis in various clinical departments.

The first in China | AIVD launched six diagnostic raw materials for self-developed new thrombosis

(Summary description)The pathological process of thrombotic diseases involves three major systems: vascular endothelium, coagulation and fibrinolysis. It has been confirmed that in the prethrombotic state, the vascular endothelium, coagulation and fibrinolysis systems have been changed. TAT, PIC, TM, t-PAIC, FDP and D-Dimer are effective responses to the early changes of the body's vascular endothelium, coagulation and fibrinolysis systems. effective indicator. It is suitable for early diagnosis and risk assessment of high-risk groups of thrombosis in various clinical departments.

  • Categories:News
  • Author:AIVD
  • Origin:
  • Time of issue:2022-04-14 09:55
  • Views:
Information

1. What is a thrombus?


According to WHO reports, in the past 30 years, the death caused by thrombosis has always accounted for more than 45% of the total death toll, far exceeding cancer and infectious diseases. Thrombosis is the common pathogenesis of stroke and ischemic heart disease, the top two fatal cardiovascular diseases in the country. The incidence of stroke in China is generally twice that of the United States, and the annual death rate is about 2 million.

 

The pathological process of thrombotic diseases involves three major systems: vascular endothelium, coagulation and fibrinolysis. It has been confirmed that in the prethrombotic state, the vascular endothelium, coagulation and fibrinolysis systems have been changed. TAT, PIC, TM, t-PAIC, FDP and D-Dimer are effective responses to the early changes of the body's vascular endothelium, coagulation and fibrinolysis systems. effective indicator. It is suitable for early diagnosis and risk assessment of high-risk groups of thrombosis in various clinical departments.

 

艾伟迪血栓产品

 

2. Clinical significance

 

Items

Clinical Significance

TAT

Indicator of prothrombin activation, elevated suggesting high blood suspicion status. Aids in the diagnosis of DIC, detects the effect of thrombolysis and recurrence of thrombosis

PIC

Indicator of fibrinolytic activation, elevated suggests thrombosis, fibrinolytic activation, aids in the diagnosis of DC or pre-DIc and other thrombotic disorders, and monitors the effect of thrombolysis

TM

Indicator of endothelial damage, elevated indicates endothelial system damage, aids in the diagnosis of DIC, atherosclerosis

t-PAIC

An indicator of endothelial injury and fibrinolytic activation, elevation can indicate endothelial injury and fibrinolytic activation, assist in the diagnosis of venous thrombosis and myocardial infarction, determine the extent of postoperative vascular endothelial system repair, and monitor the effect of thrombolysis

FDP

Fibrinolytic products, elevated to indicate fibrinolytic activation, aids in the diagnosis of primary and secondary fibrinolytic related diseases, tumors, hyperemesis, liver disease, monitoring of thrombotic disease processes

D-Dimer

Fibrinolytic products, elevated to indicate thrombosis, aids in the diagnosis of secondary fibrinolytic-related diseases, differentiates primary and secondary fibrinolysis, monitors the effect of thrombolysis and recurrence of thrombosis

 

 

3. Application scenarios

 

Test population Purpose

Project Portfolio

After orthopaedic surgery, etc. To predict the risk of thrombosis and develop a treatment plan

TAT+TM+PIC+FDP+D-Dimer

Suspected DIC Diagnose pre-DIC, DIC staging

TAT+TM+PIC+t-PAIC+FDP+D-Dimer

Suspected heart attack Diagnose pre-thrombotic state

TAT+TM+FDP+D-Dimer

Thrombolytic therapy Evaluate the effect of thrombolysis and post-thrombolysis rethrombosis monitoring

TAT+TM+PIC+FDP+D-Dimer

People over 50 years old for medical examination Screening for thrombotic risk in healthy high-risk groups

TAT+TM+PIC+t-PAIC

Infertility, hyperemesis gravidarum Evaluate coagulation and fibrinolytic function and develop treatment plan

TAT

Other patients with suspected coagulation or fibrinolytic abnormalities Evaluation of coagulation and fibrinolytic function

TAT+PIC

 

 

The six combined applications of new thrombus are helpful for the early diagnosis, treatment and monitoring of DIC: early indication of postoperative thrombosis; monitoring of the effect of anticoagulant therapy and thrombolytic therapy: diagnosis, prevention and treatment of malignant tumor coagulation monitoring.


The six new thrombus items in China are completely dependent on imported raw materials, which are expensive, long delivery time and poor specificity. Ai Weidi Bio has actively invested in research and development, independently developed and launched the first six new thrombus items (TAT, PIC, TM, t-PAIC, FDP) , D-Dimer) diagnostic raw materials and reagents in large packages, the performance is comparable to that of internationally renowned brands.

 

4. Product Information

 

Product Name

Product Catalog

Source

Pairing (coating and labeling)

Application Platforms

TM nanobodies

ABTM001

HEK293

ABTM001- ABTM002

ELISA,CLIA

TⅢ nanobodies

ABTM002

HEK293

t-PA nanobodies

ABPAIC001

HEK293

ABPAIC001- ABPAIC002

ELISA,CLIA

PAI nanobodies

ABPAIC002

HEK293

PIC nanobodies

ABPIC001

HEK293

ABPIC001- ABPIC002

ELISA,CLIA

PIC nanobodies

ABPIC002

HEK293

TAT nanobodies

ABTAT001

HK293

ABTAT001- ABTAT002

ELISA,CLIA

TAT nanobodies

ABTAT002

HEK293

 

 

Free samples of six diagnostic materials for AIVD's new thrombus! First come, first served, while stocks last. Welcome to inquire!

 

contact AIVD

相关新闻

Shenzhen AIVD Biotechnology Co. , LTD.

A4 Building 4th Floor / B5 Building C501, China Merchants Bright Technology Park, Fenghuang Street, Guangming District, Shenzhen, Guangdong Province, China

E-mail:market@aivdbiotech.com 
             info@aivdbiotech.com

Tel:+86-755-26165742   +86 18543132823

WhatsApp:+86 18543132823

facebook facebook facebook facebook facebook

© 2022 Shenzhen AIVD Biotechnology Co.,LTD.     粤ICP备18093805号